Gland Pharma Limited

rs 25

LIMITED January 23, 2023 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 National Stock Exchange of India Limi

12%

Gland Pharma Limited. 2 IGLAND] Financial Highlights (1/3) Revenue from Operations (INR Mn) - 12% 10,633 9,383 EBITDA (1) / EBITDA Margin (2) (INR Mn / %) ' 11% 13,205 32,977 28,396 3,946

11%

enue from Operations (INR Mn) - 12% 10,633 9,383 EBITDA (1) / EBITDA Margin (2) (INR Mn / %) ' 11% 13,205 32,977 28,396 3,946 3,511 10,579 36% 37% 35% 38% 35% Q3 FY22 Q3 FY23 9M FY22

36%

EBITDA (1) / EBITDA Margin (2) (INR Mn / %) ' 11% 13,205 32,977 28,396 3,946 3,511 10,579 36% 37% 35% 38% 35% Q3 FY22 Q3 FY23 9M FY22 9M FY23 Q3 FY22 Q3 FY23 9M FY22 9M FY23 PBT /

37%

TDA (1) / EBITDA Margin (2) (INR Mn / %) ' 11% 13,205 32,977 28,396 3,946 3,511 10,579 36% 37% 35% 38% 35% Q3 FY22 Q3 FY23 9M FY22 9M FY23 Q3 FY22 Q3 FY23 9M FY22 9M FY23 PBT / PAT /

35%

1) / EBITDA Margin (2) (INR Mn / %) ' 11% 13,205 32,977 28,396 3,946 3,511 10,579 36% 37% 35% 38% 35% Q3 FY22 Q3 FY23 9M FY22 9M FY23 Q3 FY22 Q3 FY23 9M FY22 9M FY23 PBT / PAT / PAT

38%

EBITDA Margin (2) (INR Mn / %) ' 11% 13,205 32,977 28,396 3,946 3,511 10,579 36% 37% 35% 38% 35% Q3 FY22 Q3 FY23 9M FY22 9M FY23 Q3 FY22 Q3 FY23 9M FY22 9M FY23 PBT / PAT / PAT Margi

15%

9M FY23 PBT / PAT / PAT Margin (3) (INR Mn / %) R&D Expenses / (R&D % of Revenue) (INR Mn / %) ■ 15% 12,381 3,656 2,730 25% 29% 25% 3,109 9,258 9,434 2,319 23% 28% 27% 7,024 23% 6.58%

25%

rgin (3) (INR Mn / %) R&D Expenses / (R&D % of Revenue) (INR Mn / %) ■ 15% 12,381 3,656 2,730 25% 29% 25% 3,109 9,258 9,434 2,319 23% 28% 27% 7,024 23% 6.58% 0.04% 699 4 695 6.54%

29%

(3) (INR Mn / %) R&D Expenses / (R&D % of Revenue) (INR Mn / %) ■ 15% 12,381 3,656 2,730 25% 29% 25% 3,109 9,258 9,434 2,319 23% 28% 27% 7,024 23% 6.58% 0.04% 699 4 695 6.54% 512

23%

% of Revenue) (INR Mn / %) ■ 15% 12,381 3,656 2,730 25% 29% 25% 3,109 9,258 9,434 2,319 23% 28% 27% 7,024 23% 6.58% 0.04% 699 4 695 6.54% 512 12 500 5.46% 0.13% 5.33% 5.20% 1,

28%

Revenue) (INR Mn / %) ■ 15% 12,381 3,656 2,730 25% 29% 25% 3,109 9,258 9,434 2,319 23% 28% 27% 7,024 23% 6.58% 0.04% 699 4 695 6.54% 512 12 500 5.46% 0.13% 5.33% 5.20% 1,714 2

Corporate Office

2

Regd. Office

1

Regd. Office

Survey N o . 143-148, 1 5 0 & 151, N e a r Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043, Telangana, Tel: +91-40-30510999 Fax: +91-40-30510800 India

Corporate Office

Plot N o . 11 & 84, T S I I C Phase: I V Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com GLAND PHARMA LIMITED Gland Pharma Limited Financial Results Q3’FY23 23rd January 2023 Cemcitibii lajectiM ■ Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these

Corporate Office

Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India BSE 543245 ®NSE GLAND Bloomberg GLAND:IN 12